Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients
Authors:
- 20 November 2010
- journal article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 38 (1) , 105-119
Abstract
The precise assessment of the dose–response to bronchodilators in the treatment of chronic obstructive pulmonary disease is hindered by the low signal to noise ratio of the typical clinical endpoint FEV1. Kinetic-pharmacodynamic (K-PD) models which use time course of response over a range of doses are in principle suited for the assessment of the dose response relationship of pulmonary administered drugs. A K-PD model was successfully developed using the longitudinal FEV1 data collected in the clinical study for a novel bronchodilator X. A superposition of two cosine functions was selected to describe the circadian variability in FEV1 at baseline. The onset (ka) and offset (kde) of drug action were described with first-order rate constants of 0.214/h and 0.141/h, respectively. Drug potency, EKD50, was estimated as 6.56 μg/h, and the maximum response, Emax as 0.631 L. Between-subject variability for kde, EKD50 and Emax were 65, 84.7 or 34.4% (expressed as coefficient variation). The model-based simulation predicted that for the same total daily dose of once-daily and twice-daily regimens, the trough FEV1 response to a twice-daily regimen was higher, and the maximum FEV1 response to once-daily regimen was higher, while the predicted average FEV1 response was about the same.Keywords
This publication has 11 references indexed in Scilit:
- Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD ModelJournal of Pharmacokinetics and Pharmacodynamics, 2006
- PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEMComputer Methods and Programs in Biomedicine, 2005
- A semimechanistic and mechanistic population PK–PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosisBritish Journal of Clinical Pharmacology, 2004
- Quantitative justification for target concentration intervention – parameter variability and predictive performance using population pharmacokinetic models for aminoglycosidesBritish Journal of Clinical Pharmacology, 2004
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Comparison of Different Methods to Evaluate Population Dose–Response and Relative Potency: Importance of Interoccasion VariabilityJournal of Pharmacokinetics and Biopharmaceutics, 1999
- Standardization of Spirometry, 1994 Update. American Thoracic SocietyAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Estimating bioavailability when clearance varies with timeClinical Pharmacology & Therapeutics, 1994
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Muscarinic receptor subtypes in airwaysLife Sciences, 1993